San Diego, CA -- (SBWIRE) -- 01/29/2014 -- An investigation on behalf of investors of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) shares over potential securities laws violations by SciClone Pharmaceuticals, and certain of its directors and officers in connection certain financial statements was announced.

If you purchased shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), you have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) concerning whether a series of statements by SciClone Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

SciClone Pharmaceuticals, Inc. reported that its annual Total Revenue rose from $72.41 million in 2009 to $156.27 million in 2012.

Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) grew from $0.83 per share in early 2009 to as high as $7.14 per share in July 2012, respectively reached $6.16 per share in July 2013.

On January 24, 2014, SciClone Pharmaceuticals, Inc. announced that the Audit Committee of the Company's Board of Directors has appointed PricewaterhouseCoopers Zhong Tian LLP to replace PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm, effective January 24, 2014.

Shares of SciClone Pharmaceuticals, Inc. declined from $5.28 per share on January 21, 2014, to $4.49 per share on January 27, 2014.

Those who purchased shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Trevor Allen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com